… gefitinib and icotinib as second-line treatment, and three patients received both gefitinib and
erlotinib … This multi-center study involved retrospective analysis. All patients were diagnosed …

… in a phase III trial (FLAURA),12 osimertinib showed a longer PFS than gefitinib or erlotinib
when … Therefore, we retrospectively evaluated patient characteristics, treatment status, and the …

… Gefitinib and erlotinib are tyrosine kinase inhibitors (TKIs) … Gefitinib plus best supportive care
in previously treated … controlled, multicentre study (Iressa survival evaluation in lung cancer) …

… to receive erlotinib (150 mg per day) or gefitinib (250 mg per … determine whether erlotinib is
superior to gefitinib in efficacy. … study, and erlotinib was not significantly superior to gefitinib in …

… MST compared with gefitinib and icotinib (P<0.05). In conclusion, gefitinib, erlotinib and
icotinib … However, gefitinib resulted in a lower frequency of fatigue, and nausea and vomiting, …

Background Median PFS in the key phase III trials with gefitinib or erlotinib for advanced
NSCLC with EGFR sensitizing mutations was less than 12 months. There are only a few data …

… been treated with erlotinib after gefitinib failure were evaluated retrospectively. Patient
characteristics … , placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer) …

… Importantly, retrospective analyses had identified these … control arms of the erlotinib and
gefitinib studies used in this meta-… of erlotinib studies. This similarity excludes any concern that …

… Therefore, we performed a retrospective study to compare the clinical efficacy among three
first-generation EGFR-TKIs as adjuvant treatment for EGFR-mutant NSCLC patients who …

… retrospectively studied gefitinib-resistant NSCLC patients with favorable clinical features,
who received erlotinib following disease progression after gefitinib … , multicentre study (Iressa …